BAXTER Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAXTER, and when can generic versions of BAXTER drugs launch?
BAXTER has two hundred and eighteen approved drugs.
There are sixteen US patents protecting BAXTER drugs. There are two tentative approvals on BAXTER drugs.
There are thirty-seven patent family members on BAXTER drugs in thirteen countries and three hundred supplementary protection certificates in fifteen countries.
Summary for BAXTER
| International Patents: | 37 |
| US Patents: | 16 |
| Tradenames: | 330 |
| Ingredients: | 129 |
| NDAs: | 218 |
| PTAB Cases with BAXTER as patent owner: | See PTAB cases with BAXTER as patent owner |
Drugs and US Patents for BAXTER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | KETOROLAC TROMETHAMINE | ketorolac tromethamine | INJECTABLE;INJECTION | 075631-002 | Jun 29, 2001 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Baxter Hlthcare | ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER | cefazolin sodium | INJECTABLE;INJECTION | 050566-004 | Jun 8, 1983 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Baxter Hlthcare Corp | BUTORPHANOL TARTRATE PRESERVATIVE FREE | butorphanol tartrate | INJECTABLE;INJECTION | 075695-001 | Oct 23, 2001 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAXTER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | ZOSYN IN PLASTIC CONTAINER | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 050750-002 | Feb 24, 1998 | 8,133,883 | ⤷ Try a Trial |
| Baxter Hlthcare | EXTRANEAL | icodextrin | SOLUTION;INTRAPERITONEAL | 021321-001 | Dec 20, 2002 | 4,761,237 | ⤷ Try a Trial |
| Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-001 | Nov 17, 1995 | 5,213,804 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAXTER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Inhalation | 99.90% | ➤ Subscribe | 2008-09-11 |
| ➤ Subscribe | Injection | 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags | ➤ Subscribe | 2014-01-31 |
International Patents for BAXTER Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2021183752 | ⤷ Try a Trial |
| New Zealand | 589290 | ⤷ Try a Trial |
| European Patent Office | 2268269 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BAXTER Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1020461 | C300482 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105 |
| 1273292 | C01273292/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009 |
| 1441735 | 08C0026 | France | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
